SUPPLEMENTAL MATERIAL

Infection model	Strain	MIC (µg/mL)	T _{f>MIC}		Reference
			Static effect	1 log reduction	-
Murine thigh infection model ^a	P. aeruginosa SR27016 ^b	0.25 ^c	53.4% ^{d,e,f}	63.3% ^{d,e,f}	1
-	5			74.2% (2 log reduction) ^{d,e,f}	
Murine lung infection model ^g	<i>P. aeruginosa</i> strains ^h	$0.5 \text{ to } 8^{k}$	43.5% ^{d,f,l}	68.5% ^{d,f,l}	2
	A. baumanni strains ¹	$0.125 \text{ to } 2^k$	68.6% ^{d,f,l}	76.2% ^{d,f,l}	_
	<i>K. pneumoniae</i> strains ^j	0.063 to 16 ^k	59.1% ^{d,f,l}	77.9% ^{d,f,l}	_
Murine thigh infection model ^a	P. aeruginosa SR27001 ^m	8 ^k	41.7% ^{d,f,l}	54.2% ^{d,f,l}	3
	<i>K. pneumoniae</i> strains ⁿ	0.125 to 16 ^k	71.0% ^{d,f,l}	80.0% ^{d,f,l}	-
	<i>E. coli</i> strains ^o	$0.125 \text{ to } 2^k$	44.7% ^{d,f,l}	54.0% ^{d,f,l}	-

Supplemental Table S1 Summary of animal infection model studies for evaluation of T_{f>MIC}

^a The male mice (5-week-old, Jcl: ICR mouse) were rendered neutropenic by intraperitoneal infection of cyclophosphamide with 150 and 100 mg/kg at 4 and 1 days before infection, respectively. Anesthetized mice were infected by intramuscular injection of bacterial suspension into thigh (n=3 to 5). Inoculation volume was 0.1 mL per site (10^5 to 10^6 CFU/mouse).

^b A cephem susceptible strain. ^c MIC was measured using CAMHB supplemented with 20 µM of apo-transferrin, i.e., iron deficient medium.

^d Single-dose serum PK studies were performed in the murine infection models. The dosing solution was subcutaneously administered to mice at 2 hours after infection. Plasma concentrations of cefiderocol were determined by LC/MS/MS.

^e In the PD studies, the administration of cefiderocol was initiated at 2 hours after infection. The total daily dose of cefiderocol was given as one dose in 24 hours, two equally divided doses every 12 hours, four equally divided doses every 6 hours, and eight equally divided doses every 3 hours, respectively. The vehicle control groups were given 0.9% saline.

^f In the PD studies, mice were dissected to take out tissue at 26 hours after infection. The samples were homogenized with MHB and the homogenates were serially diluted and incorporated into Drigalski improved medium. The plates were incubated at 37°C for 20 to 72 hours and the number of colonies was counted.

^g The male mice (5-week-old, Jcl: ICR mouse) were rendered neutropenic by intraperitoneal infection of cyclophosphamide with 150 and 100 mg/kg at 4

and 1 days before infection, respectively. Anesthetized mice were infected by intranasal instillation of bacterial suspension into thigh (n=3 to 5). Inoculation volume was 0.07 mL per site (10^5 to 10^6 CFU/mouse). For *A. baumannii* and carbapenem resistant *K. pneumoniae*, the inoculum was prepared with 5% gastric muchin to the desired concentration (bacteria:mucin=1:9).

^h Four strains including multidrug-resistant (MDR) *P. aeruginosa* (MDRP). ⁱ Six strains including MDR *A. baumannii*.

^j Three carbapenem resistant strains producing NDM-1, KPC-2 or OXA-48.

^k MIC was measured using Chelex-treated Iso-sensitest broth (ISB), i.e., iron deficient medium. One hundred grams of Chelex was added to 1 L of autoclaved medium and stirred at 4 °C for over-night. The incubated medium was filtered with 0.2 µm filter, and pH was adjusted to 7.2 to 7.4. The filtered medium was supplemented with 20 to 25 mg/L CaCl₂, 10.0 to 12.5 mg/L MgCl₂ and 10 µM ZnSO₄.

¹ In the PD studies, the administration of cefiderocol was initiated at 2 hours after infection and repeated at regular intervals of every 3 hours subsutaneously.

^m A strain of MDRP. ⁿ Nine strains producing NDM or KPC including ESBL producer and carbapenem resistant strains. ^o Two strains.

••• <u> </u>	5		
Study Single- and	Dose regimen Single dose:	Subjects	PK sampling
multiple-ascen	100, 250, 500, 1000	8 subjects per dose group	Plasma: pre-dose, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16,
ding dose	and 2000 mg single	(active 6, placebo 2)	24, 36 and 48 hours from the start of the infusion
study	infusion over 1 hour		Urine: 0-2, 2-4, 4-6, 6-8, 8-12, 12-24 and 24-48 hours from the start of the infusion
	Multiple dose:		
	1000 and 2000 mg	10 subjects per dose	Plasma:
	infusion over 1 hour	group (active 8, placebo	Day 1 (morning dose: first dose): pre-dose, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4,
	for 10 days (consist	2)	4.5, 5, 6, 8, 10, 12 and 16 hours
	of single dose on		Days 2, 3, 5, 8 and 9 (each morning dose): pre-dose
	Day 1 and		Day 10 (morning dose: last dose): pre-dose, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 3.5,
	Day 10, and		4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36 and 48 hours from the start of the infusion
	q8h from Day		Urine:
	2 to Day 9, total 26 times)		Day 1 (morning dose: first dose): 0-8 and 8-24 hours from the start of the first infusion
			Day 10 (morning dose: last dose): 0-8 and 8-24 hours from the start of the last infusion
Renal	1000 mg single	Cohorts 1 to 5	Plasma: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72
impairment	infusion over 1 hour	(normal/mild/moderate/se	hours from the start of the infusion
study		vere/ESRD requiring	Dialysate: 2-3, 3-4, 4-5, 5-6 from the start of the infusion (nominally, 4-hr
j		hemodialysis):	hemodialysis started at 2 hours after the start of the infusion)
		8 subjects per cohort (6	
		subjects in severe, 8	
		subjects in other 4	
		cohorts)	

Supplemental Table S2 Summary of clinical study designs

The summary was based on the protocol for the clinical studies presented in the references (4, 5).

ESRD: end stage of renal disease.

Supplemental Table S3 Summary of PK parameters in clinical studies

РК		Sii	up		
parameter	100 mg	250 mg	500 mg	1000 mg	2000 mg
parameter	(N=6)	(N=6)	(N=6)	(N=6)	(N=8)
C _{max}	7.76	18.9	46.6	76.4	156
$(\mu g/mL)$	(7.8)	(4.9)	(10.7)	(4.6)	(7.9)
AUC _{0-inf}	17.49	41.94	108.6	168.1	389.7
(µg·hr/mL)	(8.5)	(6.3)	(22.7)	(7.0)	(9.0)
t _{1/2}	2.00	1.98	2.12	2.26	2.74
(hr)	(4.4)	(5.5)	(15.5)	(5.8)	(10.2)
CL	5.72	5.96	4.60	5.95	5.13
(L/hr)	(8.5)	(6.3)	(22.7)	(7.0)	(9.0)
f _e	68.4	64.0	65.8	68.3	61.5
(%)	(3.2)	(5.4)	(16.2)	(6.0)	(10.6)

(a) Single- and multiple-ascending dose study

РК	Multiple dose group					
parameter	100	0 mg	1000 n	$ng(2^{nd})$	2000 mg	
Ν	8	8	8	7 ^a	8	8
Day	1	10	1	10	1	10
C _{max}	72.2	69.8	68.1	72.2	141	153
$(\mu g/mL)$	(12.0)	(13.3)	(16.2)	(11.5)	(22.7)	(12.9)
AUC ^b	177.4	160.5	172.0	168.6	338.5	366.5
(µg∙hr/mL)	(10.9)	(13.5)	(10.6)	(11.0)	(15.5)	(14.0)
t _{1/2}	2.37	2.35	2.25	2.19	2.40	2.72
(hr)	(11.4)	(18.5)	(8.8)	(4.3)	(13.2)	(21.6)
CL	5.64	6.23	5.81	5.93	5.91	5.46
(L/hr)	(10.9)	(13.5)	(10.6)	(11.0)	(15.5)	(14.0)
f_e	70.9	70.0	63.8	64.7	67.7	71.4
(%)	(6.7)	(6.1)	(12.3)	(12.8)	(4.7)	(5.3)

The summary was based on the results of clinical studies presented in the reference (4).

Geometric mean (CV% Geometric Mean).

 C_{max} : maximum plasma concentration. AUC_{0-inf}: area under the plasma concentration-time curve from time zero to infinity. $t_{1/2}$: terminal half-life. CL: total clearance. f_e : fraction of dose excreted unchanged into urine.

^a N=6 for f_e.

 $^{b}\,AUC_{0\text{-}inf}$ for Day1 and AUC over the dosing interval for Day 10.

Supplemental Table S3 (continued)

			Renal fun	ction group		
PK parameter	Normal (N=8)	Mild (N=8)	Moderate (N=7)	Severe (N=6)	ESRD (w/o HD) (N=8)	ESRD (with HD) (N=8)
C _{max} (µg/mL)	81.0 (27.4)	73.4 (21.3)	78.0 (31.1)	80.1 (19.8)	93.0 (27.8)	75.4 (31.1)
AUC _{0-inf} (µg∙hr/mL)	213.4 (26.5)	218.7 (22.2)	312.3 (38.4)	543.2 (23.6)	880.7 (24.2)	318.1 (20.3)
t _{1/2} (hr)	2.82 (16.5)	2.98 (8.4)	4.13 (12.6)	6.91 (30.6)	9.60 (33.4)	9.45 (32.8)
CL (L/hr)	4.69 (26.5)	4.57 (22.2)	3.20 (38.4)	1.84 (23.6)	1.14 (24.2)	3.14 (20.3)
V _{ss} (L)	13.5 (30.2)	14.8 (17.7)	15.4 (28.7)	16.4 (23.4)	14.2 (22.5)	26.6 (33.5)
Fu	0.420 (12.7)	0.372 (43.5)	0.353 (38.9)	0.360 (31.4)	0.424 (26.6)	0.466 (19.8)

(b) Renal impairment study

The summary was based on the results of clinical studies presented in the reference (5). Geometric mean (CV% Geometric Mean).

ESRD: end stage renal disease. w/o HD: without hemodialysis (dosing post hemodialysis). with HD: dosing prior hemodialysis. C_{max} : maximum plasma concentration. AUC_{0-inf}: area under the plasma concentration-time curve from time zero to infinity. $t_{1/2}$: terminal half-life. CL: total clearance. V_{ss} : volume of distribution at steady state. Fu: fraction of drug unbound in plasma.

Supplemental Table S4	Model development process
-----------------------	---------------------------


Model No.	Model description	OBJ	-21.1.d.	N _{parm}	Reference model
HV model					
1	3-comp model with urine output compartment, combination residual error, and IIV for CL, V1, Q2, V2, Q3, and V3	4688.084		17	
2	2-comp model with urine output compartment, combination residual error, and IIV for CL, V1, Q, and V2	4768.308	80.224	13	1
3	Model #1 without IIV for Q3 and V3	4689.062	0.978	15	1
4	Model #3 with proportional residual error	4691.928	2.866	13	3
5	Model #4 without IIV for Q2 (HV model)	4691.928	0.000	12	4
	odel using MDRD-eGFR				
6	3-comp model without urine output compartment and with proportional residual error, and IIV for CL, V1, and V2	3873.678		10	
7	Using linear model for effect of MDRD-eGFR on CL	3684.213	-189.465	11	6
8	Using piece-wise linear model for effect of MDRD-eGFR on CL	3668.895	-204.783	12	6
9	Using power model for effect of MDRD-eGFR on CL	3673.004	-200.674	11	6
10	Using piece-wise linear model with constant for MDRD-eGFR \geq 100 mL/min/1.73 m ²	3669.007	-204.671	11	6
11	Using power model for effects of body weight on V1 and V2 (final MDRD-eGFR model)	3581.534	-87.473	13	10
Incorporatio	on of CG-CrCL instead of MDRD-eGFR				
12	Using linear model for effect of CG-CrCL on CL	3628.224	-245.454	11	6
13	Using piece-wise linear model for effect of CG-CrCL on CL	3604.711	-268.967	12	6
14	Using power model for effect of CG-CrCL on CL	3621.543	-252.135	11	6
15	Using power model for effects of body weight on V1 and V2 (final CG-CrCL model)	3516.484	-88.227	14	13

-2.1.1.d.: -2 log likelihood difference. $\ N_{parm}$: the number of estimable parameters.

Supplemental Table S5 Summary of MIC to inhibit 50% and 90% of the strains for cefiderocol

Species	Number of strains	MIC ₅₀ (µg/mL)	MIC ₉₀ (µg/mL)	Reference
A. baumannii	104	0.125	2	6
P. aeruginosa	104	≤0.063	1	6
β-lactamase-producing <i>A. baumannii</i>	29	0.5	8	6
β-lactamase-producing <i>P. aeruginosa</i>	33	0.5	4	6
Enterobacteriaceae	617	≤0.063	0.5	7


MIC₅₀ and MIC₉₀: minimum inhibitory concentration to inhibit 50% and 90% of the strains, respectively.



Supplemental Figure S1 VPC for the PK model developed for healthy subjects

Semi-logarithmic y-axis. Upper figures: plasma data. Lower figures: urine data.


Supplemental Figure S2 Relationships between MDRD-eGFR and CG-CrCL



MDRD-eGFR (mL/min/1.73m^2)


Solid line: y = x.


Supplemental Figure S3 Goodness-of-fit plots for the covariate model with MDRD-eGFR.



Black solid line: y = x in upper figures and y = 0 in lower figures. Red solid line: LOESS smoother line. DV: Observed data. PRED: Population-predicted data. IPRED: Individual-predicted data. CWRES: Conditional weighted residuals.


Supplemental Figure S4





Red line: predicted median. Shaded area: 90% prediction interval. Time: time after the previous dose. Plasma concentration: 2-g dose-adjusted plasma concentration. Normal: MDRD-eGFR ≥90 mL/min/1.73 m². Mild: MDRD-eGFR 60 to <90 mL/min/1.73 m². Moderate: MDRD-eGFR 30 to <60 mL/min/1.73 m². Severe: MDRD-eGFR 15 to <60 mL/min/1.73 m². ESRD: MDRD-eGFR <15 mL/min/1.73 m².


Supplemental Figure S5 Visual predictive check for the covariate model with CG-CrCL in the range of high CG-CrCL




Red line: predicted median. Shaded area: 90% prediction interval. Time: time after the previous dose. Plasma concentration: 2-g dose-adjusted plasma concentration.


Supplemental Figure S6

Individual predicted and observed plots of plasma cefiderocol concentration data with or without 3- to 4-hour HD for the HD model




OBS: Observed data. IPRED: Individual-predicted data. W/o HD: Cefiderocol PK without non-dialysis period. With HD: Cefiderocol PK with dialysis period.





OBS: Observed data. PRED: Population-predicted data. IPRED: Individual-predicted data.

Supplemental Figure S8 Simulated typical plasma cefiderocol concentration profiles in patients requiring intermittent HD following 0.75 g q12hr dose with or without a supplemental dose of 0.75 g.



The 4-hr HD initiating at 1 hour after the end of 1st regular infusion was simulated on Days 1 and 4 assuming a three-times-a-week HD regimen. The infusion time was 3 hours.

REFERENCES

- 1. Nakamura R, Toba S, Ito A, Tsuji M, Yamano Y, Shimada J. 2014. Abstr 54th Intersci Conf Antimicrob Agents Chemother, abstr F-1559. A novel siderophore cephalosporin: V. Pharmacodynamic assessment in murine thigh infection models.
- Horiyama T, Toba S, Nakamura R, Tsuji M, Yamano Y, Shimada J. 2014. Abstr 54th Intersci Conf Antimicrob Agents Chemother, abstr F-1560. A novel siderophore cephalosporin: VI. Magnitude of PK/PD parameter required for efficacy in murine lung infection model.
- 3. Horiyama T, Toba S, Nakamura R, Tsuji M, Yamano Y, Shimada J. 2014. Abstr 54th Intersci Conf Antimicrob Agents Chemother, abstr F-1561. A novel siderophore cephalosporin: VII. Magnitude of PK/PD parameter required for efficacy in murine thigh infection model.
- 4. Shimada J, Saisho Y, Katsube T, White S, Fukase H. 2014. Abstr 54th Intersci Conf Antimicrob Agents Chemother, abstr F-1564. S-649266, a Novel Siderophore Cephalosporin for Gram Negative Bacterial Infections: Pharmacokinetics, Safety and Tolerability in Healthy Subjects.
- 5. Echols R, Katsube T, Arjona Ferreira JC, Krenz HK. 2015. Abstr 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), abstr ECCMD-1174. S-649266, a Siderophore Cephalosporin for Gram Negative Bacterial Infection: Pharmacokinetics and Safety in Subjects with Renal Impairment.
- 6. Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of S-649266, a catechol substituted siderophore cephalosporin, when tested against non-fermenting gram-negative bacteria. J Antimicrob Chemother 71:670-677.
- Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji, M, Yamano Y. 2015. In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains. Antimicrob Agents Chemother 60:729-734.